Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
49,86 USD | +4,03% | +4,90% | -16,71% |
Vakgebied
Aantal werknemers: 704
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Novel Therapeutic Compounds
100,0
%
| 75 | 100,0 % | 397 | 100,0 % | +425,83% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 75 | 100,0 % | 397 | 100,0 % | +425,83% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 54 | 25-09-09 | |
Cedric Francois
FOU | Founder | 51 | 25-09-09 |
Timothy Sullivan
DFI | Director of Finance/CFO | 53 | 01-10-17 |
Caroline Baumal
CTO | Chief Tech/Sci/R&D Officer | 57 | 03-01-23 |
Adam Townsend
COO | Chief Operating Officer | 47 | 20-11-18 |
Lukas Scheibler
CTO | Chief Tech/Sci/R&D Officer | 53 | 01-04-19 |
Meredith Kaya
IRC | Investor Relations Contact | - | - |
Jeffrey Eisele
PRN | Corporate Officer/Principal | - | 01-01-20 |
Vahe Ghahraman
LAW | General Counsel | - | 01-04-19 |
Thomas Lackner
PRN | Corporate Officer/Principal | - | 31-01-19 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Alec Machiels
FOU | Founder | 51 | 25-09-09 |
Director/Board Member | 65 | 01-07-13 | |
Andrew Dunlop
BRD | Director/Board Member | 52 | 01-03-10 |
Cedric Francois
FOU | Founder | 51 | 25-09-09 |
Founder | 54 | 25-09-09 | |
Lok Chung Chan
CHM | Chairman | 73 | 01-07-13 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 120 581 749 | 104 637 200 ( 86,78 %) | 0 | 86,78 % |
Bedrijfsgegevens
Sector
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-16,71% | 6,01 mld. | |
-4,66% | 86,13 mld. | |
+1,32% | 39,82 mld. | |
-19,27% | 30,42 mld. | |
+57,86% | 25,23 mld. | |
-16,09% | 15,35 mld. | |
-9,14% | 11,95 mld. | |
-17,69% | 11,6 mld. | |
-43,00% | 11,51 mld. | |
+5,24% | 8,71 mld. |
- Beurs
- Aandelen
- Koers APLS
- Onderneming Apellis Pharmaceuticals, Inc.